| Robotic Versus Open Pancreatoduodenectomy With Vein Resection and Reconstruction: A Propensity Score-Matched Analysis N Napoli, EF Kauffmann, M Ginesini, A Di Dato, V Viti, C Gianfaldoni, ... Annals of Surgery Open 5 (2), e409, 2024 | | 2024 |
| Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer G Aringhieri, G Di Salle, S Catanese, C Vivaldi, F Salani, S Vitali, ... Cancers 15 (22), 5391, 2023 | | 2023 |
| Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology C Vivaldi, V Genovesi, C Ugolini, L Bernardini, A Casadei-Gardini, ... Oncology, 2023 | 1 | 2023 |
| Dynamic Profiling of the Immune Tumor Microenvironment in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy I Pecora, C Ugolini, R Giannini, M Giordano, C Vivaldi, M Lencioni, ... Oncology 101 (7), 435-445, 2023 | | 2023 |
| Evolving landscape in liver transplantation for hepatocellular carcinoma: from stage migration to immunotherapy revolution S Cesario, V Genovesi, F Salani, E Vasile, L Fornaro, C Vivaldi, G Masi Life 13 (7), 1562, 2023 | 1 | 2023 |
| P-169 Early-onset biliary tract cancer: An overview of clinical presentation, risk factors, molecular profile and outcome in a multicentric Italian cohort C Vivaldi, V Genovesi, F Nichetti, V Zanuso, M Rimini, L Antonuzzo, ... Annals of Oncology 34, S75-S76, 2023 | | 2023 |
| P-402 Six-months CA19. 9 velocity as a predictive factor for relapse-free survival after curative pancreasectomy in pancreatic cancer S Cesario, L Bernardini, M Caccese, F Salani, V Massa, V Genovesi, ... Annals of Oncology 34, S154, 2023 | | 2023 |
| P-173 Extended molecular profiling in patients with biliary tract cancers: Impact of the BRCAness phenotype in patients management V Genovesi, C Vivaldi, C Congregati, M Caccese, F Salani, V Massa, ... Annals of Oncology 34, S77, 2023 | | 2023 |
| Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA1/2 (gBRCA) mutations. M Milella, G Orsi, M Di Marco, L Salvatore, L Procaccio, S Noventa, ... Journal of Clinical Oncology 41 (16_suppl), e16278-e16278, 2023 | | 2023 |
| Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) G Orsi, A Cavaliere, G Tortora, S Lonardi, M Macchini, M Di Marco, ... British Journal of Cancer 128 (5), 877-885, 2023 | | 2023 |
| Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the … M Reni, E Giommoni, F Bergamo, M Milella, L Cavanna, MC Di Marco, ... ESMO open 8 (1), 100777, 2023 | 2 | 2023 |
| Primary tumor resection for metastatic colorectal, gastric and pancreatic cancer patients: In search of scientific evidence to inform clinical practice V Fanotto, F Salani, C Vivaldi, M Scartozzi, D Ribero, M Puzzoni, ... Cancers 15 (3), 900, 2023 | 6 | 2023 |
| Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study M Niger, F Nichetti, A Casadei‐Gardini, MD Rizzato, C Pircher, M Bini, ... International Journal of Cancer 151 (8), 1310-1320, 2022 | 4 | 2022 |
| 1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations M Milella, G Orsi, A Palloni, L Salvatore, L Procaccio, S Noventa, ... Annals of Oncology 33, S1141, 2022 | 1 | 2022 |
| Pembrolizumab for first-line treatment of advanced non-small-cell lung cancer: analysis of prognostic factors of outcomes C Tibaldi, F Mazzoni, V Scotti, E Vasile, D Pozzessere, I Stasi, A Camerini, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2022 | 4 | 2022 |
| Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer L Fornaro, G Musettini, P Orlandi, I Pecora, C Vivaldi, M Banchi, F Salani, ... American Journal of Cancer Research 12 (7), 3347, 2022 | 4 | 2022 |
| Evolving pancreatic cancer treatment: From diagnosis to healthcare management M Milella, C Bassi, U Boggi, O Brunetti, A Cavaliere, S Crippa, F De Vita, ... Critical Reviews in Oncology/Hematology 169, 103571, 2022 | 21 | 2022 |
| Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. Is it still appealing in clinical trials? A meta-analysis and review of the literature F Pasqualetti, A Sainato, R Morganti, C Laliscia, E Vasile, A Gonnelli, ... Anticancer Research 41 (10), 4697-4704, 2021 | 6 | 2021 |
| 1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv) G Orsi, M Milella, F Nappo, M Di Marco, M Niger, S Bozzarelli, ... Annals of Oncology 32, S1092, 2021 | | 2021 |
| Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients A Usai, G Di Franco, M Piccardi, P Cateni, LE Pollina, C Vivaldi, E Vasile, ... Cancers 13 (16), 4131, 2021 | 13 | 2021 |
